Flag of the European Union EU Clinical Trials Register Help

Clinical trials for RNA transcription

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: RNA transcription. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-004747-23 Sponsor Protocol Number: BPC01-001 Start Date*: 2014-01-17
    Sponsor Name:Bionor Pharma ASA
    Full Title: An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization using Vacc-4x + rhuGM-CSF, and HIV-1 Reactivation using Romidepsin, on the Viral Reservoir in Virologic...
    Medical condition: HIV-infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10008919 Chronic HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003215-66 Sponsor Protocol Number: MARAVITRANS Start Date*: 2012-09-26
    Sponsor Name:FIBio Hospital Universitario Ramón y Cajal
    Full Title: EFFECT OF MARAVIROC ON THE TRANSCRIPTION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) IN RESTING CD4+ T LYMPHOCYTES IN PATIENTS ON ANTIRETROVIRAL TREATMENT WITH SUPPRESSED VIRAL LOAD
    Medical condition: HIV-infected patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001224-33 Sponsor Protocol Number: COV-HCQ Start Date*: 2020-03-25
    Sponsor Name:Universitätsklinikum Tübingen
    Full Title: Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19
    Medical condition: Acute coronavirus disease 2019
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10053983 Corona virus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000533-22 Sponsor Protocol Number: VX-950-TiDP24-C216 Start Date*: 2008-11-14
    Sponsor Name:Tibotec BVBA
    Full Title: A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Cop...
    Medical condition: Chronic genotype 1 Hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) SE (Completed) FR (Completed) AT (Completed) IT (Completed) GB (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001026-22 Sponsor Protocol Number: 1813T0835 Start Date*: 2021-03-05
    Sponsor Name:Shionogi & Co., Ltd.
    Full Title: An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Baloxavir Marboxil 2% Granules after Administration of a Single Dose to Otherwise Healthy Pediatric Patient...
    Medical condition: Influenza
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-004189-33 Sponsor Protocol Number: REK322442 Start Date*: 2013-11-28
    Sponsor Name:Haukeland University Hospital
    Full Title: ULTRADIAN SUBCUTANEOUS HYDROCORTISONE (USHI) INFUSION IN ADDISON’S DISEASE
    Medical condition: Addison`s disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000240-94 Sponsor Protocol Number: CLEAR0001 Start Date*: 2012-05-09
    Sponsor Name:Aarhus University Hospital
    Full Title: The Safety and Efficacy of The Histone Deacetylase Inhibitor Panobinostat for Purging HIV-1 from The Latent Reservoir (CLEAR) Study
    Medical condition: Human Immunodeficiency Virus (HIV) Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10020172 HIV infection NOS LLT
    14.1 10021881 - Infections and infestations 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003419-68 Sponsor Protocol Number: HepBTer Start Date*: 2020-12-18
    Sponsor Name:Academic Medical Center (AMC)
    Full Title: From fungus to virus, a phase 2a clinical trial investigating the safety and efficacy of terbinafine in chronic hepatitis B patients
    Medical condition: Chronic hepatitis B infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10052552 Hepatitis B virus LLT
    20.1 10021881 - Infections and infestations 10047450 Viral hepatitis B LLT
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    20.0 100000004848 10019743 Hepatitis B virus (HBV) LLT
    20.0 10021881 - Infections and infestations 10019737 Hepatitis B carrier LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005015-40 Sponsor Protocol Number: IVER-303 Start Date*: 2021-04-29
    Sponsor Name:Chemo Research S.L.
    Full Title: A multicentre, phase III, double-blind, randomised, parallel, placebo-controlled trial to assess efficacy and safety of early administration of Ivermectin during 3 consecutive days to prevent SARS ...
    Medical condition: Coronavirus disease (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002927-39 Sponsor Protocol Number: BOOST_TX/RESCUE_TX Start Date*: 2021-06-13
    Sponsor Name:Medical University of Vienna
    Full Title: Preventive strategies against SARS-CoV-2 in kidney transplant recipients: Intervention A – vaccination: Single blinded randomized controlled trial on BNT162b2 or mRNA-1273 (mRNA) vs Ad26COVS1 or C...
    Medical condition: Intervention A - vaccination Patients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following two doses of an mRNA vaccine Substudy A: kidne...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001966-13 Sponsor Protocol Number: EDP938-201 Start Date*: 2021-07-07
    Sponsor Name:Enanta Pharmaceuticals, Inc.
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY TO EVALUATE EDP-938 REGIMENS IN SUBJECTS AGED 28 DAYS TO 36 MONTHS INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV)
    Medical condition: Respiratory Syncytial Virus (RSV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) ES (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-002154-70 Sponsor Protocol Number: CP40559 Start Date*: 2019-10-24
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF BALOXAVIR MARBOXIL IN OTHERWISE HEALTHY PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 1 YEAR WITH IN...
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022001 Influenza (epidemic) LLT
    20.1 100000004862 10022003 Influenza B virus infection LLT
    20.1 100000004862 10022002 Influenza A virus infection LLT
    20.0 100000004862 10016790 Flu LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed) ES (Ongoing) FI (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-001529-30 Sponsor Protocol Number: EDP938-102 Start Date*: 2020-09-29
    Sponsor Name:Enanta Pharmaceuticals, Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection with Respiratory Syncytial Virus in Ambula...
    Medical condition: Respiratory syncytial virus (RSV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) NL (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002139-94 Sponsor Protocol Number: IPH1101-203 Start Date*: 2007-06-19
    Sponsor Name:Innate Pharma
    Full Title: Multiple dose Phase II study of IPH1101 in monotherapy or associated with a low dose of IL2 (2MIU) in non previously treated hepatitis C patients
    Medical condition: Non previously treated Hepatitis C patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003836-77 Sponsor Protocol Number: OCTO-003 Start Date*: 2008-12-09
    Sponsor Name:University of Oxford
    Full Title: AspECT - A phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia & oesophagitis.
    Medical condition: Barrett's Metaplasia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001684-89 Sponsor Protocol Number: RG_20-030 Start Date*: 2020-05-05
    Sponsor Name:University of Birmingham
    Full Title: CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection.
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004855 10047468 Viral lower respiratory tract infections HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-004971-30 Sponsor Protocol Number: FLUGEN-H3N2-V002 Start Date*: 2018-04-27
    Sponsor Name:FluGen, Inc
    Full Title: A Phase 2a Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Bris10 M2SR (H3N2 A/Brisbane/10/2007) Vaccine Administered as a Single Intranas...
    Medical condition: Prophylactic H3N2(A/Brisbane/10/2007) monovalent influenza vaccine, Bris10 M2SR, for protection against influenza disease caused by seasonal influenza A viruses.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000338-16 Sponsor Protocol Number: 42847922MDD3002 Start Date*: 2020-10-27
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Eld...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) FI (Prematurely Ended) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-000641-33 Sponsor Protocol Number: PAX Start Date*: 2022-04-21
    Sponsor Name:Fundació FLS de Lluita contra la Sida, les Malalties Infeccioses i la Promoció de la Salut i La Ciència
    Full Title: Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study
    Medical condition: Post-Acute-Covid-19 Syndrome
    Disease: Version SOC Term Classification Code Term Level
    24.0 10021881 - Infections and infestations 10085503 Post-acute COVID-19 syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012280-34 Sponsor Protocol Number: 26866138-LYM-2034 Start Date*: 2009-12-04
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, ...
    Medical condition: Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) CZ (Completed) DE (Completed) FR (Completed) ES (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 24 10:55:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA